1
Life Sciences 1aLecture Slides Set 10Fall 2006-2007Prof. David R. Liu
N N
HO OH
O
O
NH
O
HN
N
S S
N
Lectures 17-18: The molecular basis of drug-protein binding:
HIV protease inhibitors
1. Drug development and its impact on HIV-infected patients
2. Energetic dissection of a small molecule binding to a protein
a. Enthalpy changes upon binding
b. Entropy changes upon binding
3. Case studies of saquinavir and ritonavir, two small-molecule HIV
protease inhibitors
a. Fill hydrophobic pockets with hydrophobic groups
b. Provide complementary hydrogen bond donors and acceptors
c. Mimic the transition state of a reaction
d. Maximize the rigidity of the drug
e. Displace bound water molecules Required: Lecture NotesMcMurray p. 808-810, 640-642
Lecture Readings
2
Impact of Anti-HIV Drugs• 1990s: anti-HIV drugs transform HIV infection from a short
death sentence to a chronic (but very serious) illness• 13 FDA-approved drugs inhibit HIV reverse transcriptase; 9
drugs inhibit HIV protease (first approved December, 1995)• Mortality rate of U.S. patients with advanced AIDS:
• 29% per year in 1995• 9% per year in mid-1997
• 1997-2003: Death rate from AIDS in Europe falls 80%• Gains primarily attributed to combination therapy involving
HIV protease inhibitors + other antiretroviral agents
Drug Development is Very Difficult
• Total cost to develop a drug = ~$1 billion + ~10-15 years
3
1) Potency (affinity)
Successful Drugs Must Satisfy ManyChemical and Biological Requirements
+Keq = Ka = 1÷Kd
drug-protein complexdrug protein target
targetnon-target non-target non-target
2) Specificity (toxicity, immunogenicity)
oralcellular
3) Bioavailability
k inactive or toxic4) Biostability 5) Economics
Lectures 17-18a: The molecular basis of drug-protein binding:
HIV protease inhibitors
1. Drug development and its impact on HIV-infected patients
2. Energetic dissection of a small molecule binding to a protein
a. Enthalpy changes upon binding
b. Entropy changes upon binding
3. Case studies of saquinavir and ritonavir, two small-molecule HIV
protease inhibitors
a. Fill hydrophobic pockets with hydrophobic groups
b. Provide complementary hydrogen bond donors and acceptors
c. Mimic the transition state of a reaction
d. Maximize the rigidity of the drug
e. Displace bound water molecules
4
H
O H
HO
H
H
O
H
solvatedsubstrate
solvatedproteinbindingpocket
protein-substratecomplex
Enthalpy Changes (ΔH) Involving WaterUpon Drug-Protein Binding
H
O H
water moleculesreleased into bulk
solvent
• Interactions with water can play crucial roles in binding!
H O
H
H
O
H
H
O H
HOH
Drug-Protein BindingEnthalpy (H) Balance Sheet
• Loss of some protein-water interactions: ΔHP-W > 0*• Loss of some drug-water interactions: ΔHD-W > 0** These losses are minimized when the drug and protein
binding pocket are more hydrophobic• Gain of some drug-protein interactions: ΔHD-P < 0**
• Van der Waals • Hydrogen bonding • Ionic bonding** These gains are maximized when D & P are complementary• Gain of water-water interactions: ΔHW-W < 0
Keq = Ka = 1÷Kd
drug-protein complexdrug (D) protein (P)water (W)
H2O H2O
water (W)
H2O
H2O
5
Loss of Entropy Upon Binding
+
• Two freely rotating and translating molecules uponbinding form one complex
• Both the protein and drug often become more rigid uponbinding, leading to additional entropy loss
Releasing Water Molecules into “BulkSolvent” is Entropically Favorable
H
O H
HO
H
HO
H
HO
H
H
OH
HO
H
H
OH
H
OH
H
OH
H
O H HO
H
HO
H
H
OH
H
OH
+
H
O H
HO
H
HO
H
HO
H
HO
H
HO
H
H
OH
H
OH
H
OH
+
H O
H
H O
H
H O
H
HOH
HO
H
• Recall: the increase in entropy as water molecules are releasedinto “bulk solvent” is the basis of the hydrophobic effect
bulk water
6
Drug-Protein BindingEntropy (S) Balance Sheet
• Protein loses translational and rotational entropy: ΔSP < 0• Drug loses translational and rotational entropy: ΔSD < 0• Protein and drug rigidity increases: ΔSD < 0*, ΔSP < 0*
* To minimize this loss, pre-rigidify the drug• Bound water gains entropy when released: ΔSW > 0**
** To maximize this gain, design the drug to displace boundwater molecules wherever possible
Keq = Ka = 1÷Kd
drug-protein complexdrug (D) protein (P)water (W)
H2O H2O H2O
water (W)
H2O
Changes in Free Energy and EntropyUpon Drug-Protein Binding
ΔG = ΔH – TΔSG = Free energyH = Enthalpy (heat)T = Temperature in KelvinS = Entropy (disorder)
• In general, for ΔG of binding to be negative (favoring binding):Favorable enthalpic interactions (ΔHP-D < 0) between theprotein and drug and favorable changes in the entropy ofwater (ΔSwater > 0) must overcome…Unfavorable entropy loss in the protein and drug (ΔSP andΔSD < 0), as well as the loss of enthalpic interactionsbetween water and the protein or small molecule (ΔHP-Wand ΔHD-W> 0)
7
Lectures 17-18a: The molecular basis of drug-protein binding:
HIV protease inhibitors
1. Drug development and its impact on HIV-infected patients
2. Energetic dissection of a small molecule binding to a protein
a. Enthalpy changes upon binding
b. Entropy changes upon binding
3. Case studies of saquinavir and ritonavir, two small-molecule HIV
protease inhibitors
a. Fill hydrophobic pockets with hydrophobic groups
b. Provide complementary hydrogen bond donors and acceptors
c. Mimic the transition state of a reaction
d. Maximize the rigidity of the drug
e. Displace bound water molecules
Two HIV Protease Inhibitors
ritonavir(Abbot)
saquinavir(Hoffmann-La Roche)
OH
N
H
H
O NH
CH3CH3CH3
HN
O
NH
O
N
O
NH2
O
HN
OH
NH
O
O
N
SNH
O
N
CH3
N
S
H3C
H3C
8
Hydrophobic Surface Complementarity:Saquinavir and HIV Protease
OH
N
H
H
O NH
CH3CH3CH3
HN
O
NH
O
N
O
NH2
Pro 81
Val 82Ile 84
Leu 23 • The hydrophobic groupsof saquinavir fit preciselyinto hydrophobic bindingpockets in HIV protease
Hydrophobic Surface Complementarity:Saquinavir and HIV Protease
OH
N
H
H
O NH
CH3CH3CH3
HN
O
NH
O
N
O
NH2
Pro 81
Val 82Ile 84Leu 23
• Filling hydrophobicpockets increases Vander Waals interactions(ΔHD-P < 0) andincreases thedisplacement of water(ΔSW > 0)
9
Pro 81
Val 82Ile 84
Leu 23
Hydrophobic Surface Complementarity:Saquinavir vs. the “Runner-Up” Candidate
Pro 81
Val 82Ile 84
Leu 23
OH
N
H
H
O NH
CH3CH3CH3
HN
O
NH
O
N
O
NH2
No hydrophobic group tocomplement binding pocket
saquinavir
OH
N
O NH
CH3CH3CH3
HN
O
NH
O
N
O
NH2
runner-up
~10-fold worsebinding than
saquinavir
• Removing one of the hydrophobic pocket-filling groups ofsaquinavir (only 4 carbons!) greatly reduces binding potency
Hydrophobic Surface Complementarity:Ritonavir and HIV Protease
Animation rendered by Brian Tse
10
Leu 23
Ile 84
Val 82
Pro 81
Hydrophobic Surface Complementarity:Ritonavir and HIV Protease
O
HN
OH
NH
O
O
N
SNH
O
N
CH3
N
S
H3C
H3C
• The hydrophobicgroups of ritonaviralso complementthe hydrophobicbinding pockets inHIV protease
Leu 23Ile 84
Val 82 Pro 81
Hydrophobic Surface Complementarity:Ritonavir and HIV Protease
• Multiple structurescan fill the samepocket, especiallywith someenzyme flexibility
O
HN
OH
NH
O
O
N
SNH
O
N
CH3
N
S
11
HIV Protease Changes Shape SlightlyWhen Binding Saquinavir vs. Ritonavir
Leu 23Ile 84
Val 82 Pro 81
HIV Protease + Ritonavir
Pro 81
Val82
Ile 84Leu 23
HIV Protease Changes Shape SlightlyWhen Binding Saquinavir vs. Ritonavir
HIV Protease + Saquinavir
12
Hydrogen Bonding: Saquinavir andHIV Protease
N
H
H
OHN
OH
O
NHO
N
CH3
CH3CH3
NH
H H
O
N
O
H
O NH2
N N
H H
Ile50 Ile50'
• Saquinavircomplementshydrogen bonddonors providedby the enzyme,enhancingfavorable(negative) ΔHD-P
HN
O
O
N
S
NH
O
N
CH3N
S
H3C
H3C
HO
O
H H
O
N
O
H
N N
H H
Ile50 Ile50'
Hydrogen Bonding: Ritonavir andHIV Protease
• H-bonds between small molecules and proteins help tooffset the penalty of giving up H-bonds to water upon binding
13
O
HN
O
O
H
O
OH
O H
‡
Substrate, Transition State, andIntermediate of HIV Protease
O
HN
O
O
O
OH
O HH
transition state tetrahedralintermediate
O
HN
O
O
H
O
O
substrate
enzyme
δ–
δ–
O
HN
OH
NH
O
O
N
SNH
O
N
CH3
N
S
H3C
H3C
Transition State Analogs
tetrahedral transitionstate mimic
O
HN
HH
better mimic, butchemically unstable
O
C
HH
H H
OH
N
H
H
O NH
CH3CH3CH3
HN
O
NH
O
N
O
NH2
saquinavirritonavir
O
HN
O H
transition state
• Enzymes can bind transition states mimics very potently
14
Rigid Versus Flexible Inhibitors
Dupont-Merck inhibitor
cyclic, rigidcore
N N
HO OH
O
O
NH
O
HN
N
S S
N
more potentbinding
• Rigidity reduces entropy lost upon binding (less negative ΔSD)
More flexible variant
N N
HO
OHO
ONH
O
HN
N
S
S
N
N N
HO
OHO
ONH
O
HN
N
S
S
N
N N
HO OH
O
O
NH
O
HN
N
S S
N
weakerbinding
N N
H H
Ile50 Ile50'
N N
HO OH
O
O
NH
O
HN
N
S S
N
N N
HO OH
O
O
NH
O
HN
N
S S
N
Water-Liberating Inhibitors
H H
O
N N
H H
Ile50 Ile50'
+
+H H
O
Dupont-Merck inhibitor
liberated water
15
Replacing a Bound Water MoleculeWith a Small-Molecule Group
Ile 50
water
HIV protease + substrate
Ile 50carbonyl oxygenreplaces water
HIV protease + Dupont-Merck inhibitor
• The Dupont-Merck inhibitor replaces the bound water in theHIV protease active site with a carbonyl oxygen
• Releasing bound water is entropically favorable (ΔSw > 0)
Key Points: Molecular Basis of Drug Binding• Drug development has had a major impact on society and
on the lives of patients infected with HIV
• Effective drugs must meet several chemical and biologicalrequirements, including potent binding to a target
• The combination of enthalpic and entropic changes thatoccur upon small molecule-protein binding ultimatelydetermines the binding potency (Kd) of a drug
• HIV protease inhibitors bind favorably by (i) fillinghydrophobic pockets with complementary hydrophobicgroups, (ii) providing hydrogen bonding partners,(iii) mimicking the amide hydrolysis transition state, (iv)being rigid, and (v) releasing bound water molecules